View Older Stories
-
H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)
-
Crinetics (CRNX) PT Raised to $97 at Jones Trading
-
Crinetics (CRNX) PT Raised to $80 at Morgan Stanley
-
Baird on Crinetics (CRNX): 'Palsonify off to a great start, expect upwards revision to estimates'
-
Crinetics (CRNX) PT Raised to $90 at Evercore ISI
-
Stifel Reiterates Buy Rating on Crinetics (CRNX)
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
Piper Sandler on Biotechnology: 'What Commercial Names to Own in 2026?'
-
Crinetics Pharmaceuticals (CRNX) Misses Q3 EPS by 13c
-
Piper Sandler on Crinetics (CRNX): 'We Are Buyers and Continue to Be Bullish'
-
Crinetics (CRNX) PT Raised to $87 at Oppenheimer
-
Crinetics (CRNX) PT Raised to $75 at Stifel
-
Piper Sandler: 'We Remain Bullish on Crinetics (CRNX)'
-
Crinetics (CRNX) PT Raised to $88 at Leerink Partners
-
Crinetics (CRNX) PT Raised to $77 at Morgan Stanley
-
Stifel Reiterates Buy Rating on Crinetics (CRNX)
-
Crinetics (CRNX) PT Raised to $85 at Jones Trading
-
H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Crinetics (CRNX)
-
Oppenheimer Reiterates Outperform Rating on Crinetics (CRNX)
-
Crinetics (CRNX) PT Raised to $62 at Baird
-
Crinetics (CRNX) PT Raised to $143 at Citizens JMP
-
Cantor Fitzgerald Reiterates Overweight Rating on Crinetics (CRNX)
-
Crinetics receives FDA orphan drug designation for CAH treatment
-
Crinetics (CRNX) PT Lowered to $86 at Citizens JMP
-
Crinetics (CRNX) PT Lowered to $65 at Jones Trading
-
Crinetics (CRNX) PT Lowered to $58 at Stifel, 'Building Commercial Launch Readiness Ahead of 9/25 PDUFA'
-
Crinetics Pharmaceuticals (CRNX) Misses Q2 EPS by 13c
-
Piper Sandler: 'We Remain Bullish on Crinetics (CRNX)'
-
H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)
-
Jones Trading Reiterates Buy Rating on Crinetics (CRNX)
-
Citizens JMP Reiterates Market Outperform Rating on Crinetics (CRNX)
-
Goldman Sachs Starts Crinetics (CRNX) at Neutral
-
Citizens JMP Reiterates Market Outperform Rating on Crinetics (CRNX)
-
H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)
-
H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)
-
Crinetics Pharmaceuticals (CRNX) Misses Q1 EPS by 11c
-
Piper Sandler: 'What Biotech Names to Own in Market Volatility'
-
Stifel shares update on CAH stocks following conversation with physicians
-
Stifel Starts Crinetics (CRNX) at Buy
-
Crinetics (CRNX) PT Raised to $100 at Cantor Fitzgerald
-
Crinetics (CRNX) PT Lowered to $91 at Citizens JMP
-
Crinetics Pharmaceuticals (CRNX) Reports In-Line Q4 EPS
-
Crinetics Pharmaceuticals (CRNX) Appoints Tobin Schilke as CFO
-
TD Cowen Starts Crinetics (CRNX) at Buy
-
JMP Securities Biotechnology Overview
-
Jefferies Upgrades Crinetics (CRNX) to Buy
-
Oppenheimer Reiterates Outperform Rating on Crinetics (CRNX)
-
Crinetics Pharmaceuticals (CRNX) Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
-
Piper Sandler Reiterates Overweight Rating on Crinetics (CRNX); 'We Remain Highly Bullish on CRNX'

